Last month, the private company StimRelieve, LLC, received approval from the United States Food & Drug Administration (FDA) to conduct a clinical trial of a stimulation device to treat chronic migraine. Called the StimRelieve Halo Migraine System, it is implanted under the skin and uses wireless neurostimulators to treat chronic migraine—migraine 15 or more days per month—that has not responded to other treatment. Continue Reading
Last month the U.S. Food and Drug Administration (FDA) approved Treximet (sumatriptan and naproxen sodium) for use in pediatric patients 12 years of age and older for the acute treatment of migraine with or without aura. Continue Reading
The Pennsylvania-based company, OptiNose, recently announced that a pivotal phase III study evaluating the efﬁcacy and safety of the device, called AVP-825, will be published in the January 2015 issue of Headache, The Journal of Head and Face Pain. The study is currently available on the journal’s website through its early access feature. Continue Reading
Medications to prevent migraine have been slow in coming, but a treatment approach currently being studied suggests that a new type of drug may benefit countless migraineurs. This new method employs agents that block a protein called calcitonin gene-related peptide (CGRP), which plays a crucial role in migraine. The new drugs, anti-CGRP antibodies, bind to the protein and stop it from attaching to nerve receptors, preventing migraine in the process. Continue Reading
The U.S. Food and Drug Administration recently cleared the handheld device, SpringTMS, for the treatment of acute migraine with aura.
SpringTMS, available by prescription, creates mild electrical currents that can depolarize neurons in the brain. Experts believe this action interrupts the abnormal hyperactivity associated with migraine. When treating themselves, patients simply hold the device at the back of their head and press a button. Continue Reading